Hemin
- Generic Name
- Hemin
- Brand Names
- Panhematin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 16009-13-5
- Unique Ingredient Identifier
- 743LRP9S7N
- Background
Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand.
- Indication
Used in the management of porphyria attacks, particularly in acute intermittent porphyria.
- Associated Conditions
- Acute Porphyria, Hereditary Coproporphyria (HCP), Variegate Porphyria
- Associated Therapies
- -
Acute Porphyria Biomarkers for Disease Activity
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2024-04-16
- Target Recruit Count
- 50
- Registration Number
- NCT02935400
- Locations
- 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States
Hemin to Prevent Post-ERCP (Endoscopic Retrograde Cholangiopancreatography) Acute Pancreatitis
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Erasme University Hospital
- Target Recruit Count
- 284
- Registration Number
- NCT01855841
- Locations
- 🇧🇪
Hôpital Ambroise Paré, Mons, Belgium
🇧🇪Erasme Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium
🇧🇪CHU Brugmann, Brussels, Belgium
Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS
- First Posted Date
- 2007-04-30
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 6
- Registration Number
- NCT00467610
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath